Relmada Therapeutics, Inc. (FRA:4E2)

Market Cap	271.72M
Revenue (ttm)	n/a
Net Income (ttm)	-47.88M
Shares Out	n/a
EPS (ttm)	-1.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,328
Average Volume	66
Open	3.600
Previous Close	3.960
Day's Range	3.600 - 3.940
52-Week Range	0.212 - 3.960
Beta	n/a
RSI	54.22
Earnings Date	Mar 27, 2026

About Relmada Therapeutics

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 17
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4E2

Financial Performance

Financial numbers in USD